Press Releases

May 20, 2020
BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference    read more...
May 15, 2020
BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II    read more...
May 14, 2020
BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress    read more...
May 11, 2020
BeiGene Reports First Quarter 2020 Financial Results    read more...
Apr 30, 2020
Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19    read more...
Apr 29, 2020
BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting    read more...
Apr 20, 2020
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China    read more...
Apr 13, 2020
BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis    read more...
Apr 10, 2020
China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma    read more...
Mar 25, 2020
BeiGene Announces Supply Update for ABRAXANE® in China    read more...
Mar 02, 2020
BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results    read more...
Feb 28, 2020
MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors    read more...
Feb 25, 2020
BeiGene to Present at the Cowen and Company’s 40th Annual Health Care Conference    read more...
Jan 21, 2020
BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis    read more...
Jan 13, 2020
EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA®▼ in Greater China    read more...
Jan 08, 2020
BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference    read more...
Jan 04, 2020
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing    read more...
Jan 02, 2020
BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment    read more...
Dec 27, 2019
China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Classical Hodgkin’s Lymphoma Who Have Received at Least Two Prior Therapies    read more...
Dec 22, 2019
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID® in Relapsed or Refractory Indolent Lymphoma    read more...